



BioCryst UK Ltd

**Methodological Note Supporting the Disclosure Report for
Transfers of Value in 2023**

Introduction

This methodology note describes the methods used by BioCryst UK Ltd to meet its obligations and the requirements for disclosing payments and Transfers of value (ToV) to Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and Other Relevant Decision Makers (ORDMs) as outlined in the EFPIA HCP/HCO Code of Practice and reflected in the ABPI Code of Practice for the Pharmaceutical industry.

Transfers of Values made to Patient Organisations (PtOrgs) are disclosed separately on the BioCryst UK website:- <https://biocryst.co.uk/disclosures/>

Acronyms and Abbreviations

Healthcare Professional (HCP)	Anyone that is a member of the medical, dental, pharmacy or nursing professions and any other professional that may administer, prescribe, purchase, recommend or supply a medicine.
Healthcare Organisation (HCO)	A healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university, or other teaching institution or learned society, or an entity through which an HCP (as defined above) or other relevant decision makers provide a service.
Other Relevant Decision Maker (ORDM)	The term 'other relevant decision maker' particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals
Patient Organisations (PtOrgs)	An organisation mainly comprising of patients and/or caregivers or any user organisation such as a disability organisation, carer or relative organisation and consumer organisation that represents and/or supports the needs of patients and/or caregivers.
Professional Conference Organiser (PCO)	a company which specialises in the organisation and management of congresses, conferences, seminars and similar events.
Transfer of Value (ToV)	Direct and indirect transfers of value, whether payments, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of prescription-only Medicinal Products exclusively for human use. Direct transfers of value are those made directly by a Member Company for the benefit of a Recipient. Indirect transfers of value are those made on behalf of a Member Company for the benefit of a Recipient, or transfers of value made through an intermediate and where the Member Company knows or can identify the HCP/HCO that benefit from the Transfer of Value.

Member Company	as defined in the EFPIA Statutes, means research-based companies, developing and manufacturing Medicinal Products in Europe for human use.
Recipient	Any HCP or HCO/PCO as applicable, in each case, whose primary practice, principal professional address or place of incorporation is in Europe.

Transfer of Value Categories

The following table defines what transfers of value are reported in which EFPIA category and subcategory.

EFPIA category	EFPIA subcategory	Example Activities
Donations and Grants (HCOs only)	N/A	<ul style="list-style-type: none"> • Charitable contributions • Business Donations • Educational grants (e.g. fellowships, courses provided by an HCO where BioCryst does not select the individual HCPs participating) • Sponsoring of speakers/faculty which by nature of purpose and funding are classified under educational grants
Contribution to Cost of Events	Sponsorship agreements (HCOs only)	<ul style="list-style-type: none"> • Placement of a brand logo in a conference program or invitation communication in exchange for supporting the program • Funding an event in return for a display booth • Funding an event in exchange for advertising space • Other advertisement space (in paper, electronic or other format) • Satellite symposia at a congress • Any other activity qualified as “Corporate Sponsorship” according to BioCryst Anti-Corruption Policies • Sponsoring of speaker/faculty and sponsoring courses provided by an HCO which are qualified as “Corporate Sponsorship” according to BioCryst Anti-Corruption Policies • For contributions provided to Events through Professional Conference Organisers (PCOs): TOVs through PCOs are reported as follows: either in the name of benefitting HCO or in the name of Recipient PCO
	Registration fees	<ul style="list-style-type: none"> • Registration fees paid for the HCP/HCO to attend events
	Travel & Accommodation	<ul style="list-style-type: none"> • Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking, shared ground transportation) • Accommodation • Travel Visa

Fee for services and consultancy	Fees	<ul style="list-style-type: none"> • Speaker engagements • Advisory Boards* • Study-related engagements • Preceptorships • Post-marketing surveillance studies • Non-Interventional Studies that are Retrospective in nature • Medical writing • Data analysis • Development of education materials • General consulting / advising • Speaker training if linked to a speaker engagement • Any other activity which qualifies as General Consultancy according to BioCryst's Anti-Corruption Policies
	Related expenses	<ul style="list-style-type: none"> • Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) • Accommodation • Travel Visa
Research and Development Transfers of Value	N/A	<ul style="list-style-type: none"> • Clinical Trials • Data Monitoring Committees related to studies • Non-Interventional Studies that are Prospective in nature • Investigators Initiated Research (IIR) • Investigator Sponsored Research (ISR) • Clinical & Research Collaboration

* excluding Data Monitoring Committees related to studies which are disclosed in aggregate under R&D

Cross border payments and Consent for Transfer of Value Reporting

BioCryst UK Ltd collates cross border payments from BioCryst Pharmaceuticals Inc together with all its Affiliates ('BioCryst') and reports the transactions where the recipient has its principal practice in the UK.

Multi-year contracts

For contracts that span more than 1 year (Multi- year contracts), only transfers of value made during year 2023 will be included in the 2023 disclosure. The remainder of the contract values will be disclosed in future disclosure.

Private Companies

Where an HCP/ORDM runs a private company, this organisation has been designated an HCO. Where a contract has been signed with the HCO as the employer, BioCryst will report the ToV against the HCO

Consent Collection

Consent for the publication of the ToVs was obtained and documented as such before disclosing the data on an individual HCP/HCO level where applicable. Consent management procedures were conducted in alignment with the UK Data Protection Act 2018 and EU General Data Protection Regulation.

Consent was obtained either on Recipient level for all ToVs during a given period of time not shorter than one full year or on spend level for each interaction or single ToVs.

BioCryst does not accept partial consent or split disclosure.

In case consent was either not given by the Recipient or not documented sufficiently to prove the existence of consent, ToVs are disclosed on aggregate level only.

In the event of death of an HCP by the time of disclosure (by the publication date) the ToV is reported in aggregate.

HCP's have a right to withdraw their consent at any time. Consent withdrawal has been assessed according to the relevant BioCryst local data privacy laws and withdrawal of consent will have retroactive effect on past events and consultancies provided BioCryst has not already had to report the data to the ABPI to meet the annual disclosure requirement. If the latter is the case, then the withdrawal of consent would only be effective for the future.

Currency & VAT

All disclosed values are in Pound Sterling (GBP). The financial values provided exclude Value Added Tax. Where a payment was fulfilled in another currency the value was converted into Great British Pounds based on the exchange rate at the time of payment.

Published Data

BioCryst applies the EFPIA definition of "Form of Disclosure" as outlined in EFPIA Disclosure Code Article 23.4 - pursuant to clause 28-31 of the 2021 ABPI Code of Practice.

This 2023 calendar year BioCryst Disclosure Report will be submitted to the ABPI disclosure database by the end of March 2024. It will be published by the ABPI on 30 June 2024.

This data will remain published for 3 years in the public domain and stored for a minimum of 5 years on record by BioCryst.

Member Companies shall be able to modify, delete or in any way alter their disclosures at any time after the time of publication. The information disclosed shall remain in the public domain for 3 years after the time such information is first published.